Bone metabolism in childhood rheumatic disease

Rheumatic Disease Clinics of North America

Volumn 28, Issue 3, 2002, Pages 655-667

  Rabinovich, C Egla ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; VITAMIN D;

ARTICLE; BONE DENSITY; BONE GROWTH; BONE METABOLISM; CALCIUM INTAKE; CHILD; CHILDHOOD DISEASE; DISEASE ACTIVITY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RHEUMATIC DISEASE; SIDE EFFECT;

EID: 0036697785     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00017-0     Document Type: Review

References (87)

1. Rodan GA. Introduction to bone biology. Bone 1992;13:S3-6.
2. Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th edition. Philadelphia: Lippencott, Williams & Wilkins. 1999. p. 30-2.
3. Watrous DA, Andrews BS. The metabolism and immunology of bone. Semin Arthritis Rheum 1989;19:45-65.
4. Owen M. Histogenesis of bone cells. Calcif Tissue Res 1978;23:103-12.
5. Grigoriadis AE, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in bone derived clonal cell population: effect of dexamethasone. J Cell Biol 1998;106:2139-51.
6. Raisz LG, Kream BE. Regulation of bone formation N Engl J Med 1983;309:29-35.
7. Gronthos S, Graves SE, Ohta S, Simmons PJ. The STRO-1 fraction of adult human bone marrow contains the osteogenic precursors. Blood 1994;84:4164-73.
8. Joyner CJ, Bennett A, Triffitt JT. Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies. Bone 1997;21:1-6.
9. Akesson K. Ljunghall S Jonsson B, Sernbo I, Johnell O, Gardsell P, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995;10:1823-9.
10. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-406.
11. Van der Sluis IM, de Muinck Keizer-Schrama SMPF. Osteoporosis in childhood: bone density of children in health and disease. J Pediatr Endocrinol Metab 2001;14:817-32.
12. Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S, et al. Serum bone alkaline phosphatases isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 1997;82:2056-61.
13. Whyte MP. Hypophosphatasia and the role of alkaline phosphatases in skeletal maturation. Endocr Rev 1994;15:439-61.
14. Johansen JS, Mølholm Hansen JE, Christiansen C. A radioimmunoassay for bone Gla protein in human plasma. Acta Endocrinol 1987;114:410-6.
15. Delmas PD. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 1992;13:S17-21.
16. Gundberg CM, Lian JB, Gallop PM, Steinberg JJ. Urinary gamma-carboxyglutamic acid and srum osteocalcin as bone markers: studies in osteoporosis and Paget's disease. J Clin Endocrinol Metab 1983;57:1221-5.
17. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int 1996;58:236-43.
18. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-32.
19. Melkko J, Kauppila S, Niemi S Risteli L, Haukipuro K, Jukkola A, et al. Immunoassay for intact aminoterminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
20. Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta 2001;313:95-105.
21. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997; 43:2058-63.
22. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
23. Black D, Duncan A, Robins SP. Quantitative anaysis of the pyridinium crosslinks of collagenin urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 1988;169:197-203.
24. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
25. Cheung CK, Panesar NS, Haines C, Masari J, Swaminathan R. Immunoassay of tartate-resistant acid phosphatase in serum. Clin Chem 1995;41:679-86.
26. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series. Geneva: WHO, 1994.
27. Kanis JA, Melton J, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Mineral Metabol 1994;9:1137-41.
28. Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int 1991;49:90-4.
29. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
30. Cummings SR, Black DM, Nevitt MD, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fracture. Lancet 1992;341:72-5.
31. Theintz B, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992;75:1060-5.
32. Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Andon JK, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross sectional model. J Clin Invest 1994;93:799-808.
33. Rubin K, Schirduan V, Gendreau P, Sarfarazi M, Mendola R, Dalsky G. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. J Pediatr 1993;123:863-70.
34. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73:555-63.
35. Gilsanz V, Gibbens DT, Roe TF, Carlson M, Senac MO, Boechat MI, et al. Vertebral bone density in children: effect of puberty. Radiology 1988;166:847-50.
36. Johnston CC, Slemenda CW. Pathogenesis of osteoporosis. Bone 1995;17:S19-22.
37. Chestnut CH. Theoretical overview: bone development, peak bone mass, bone loss, and fracture risk. Am J Med 1991;91:S2-4.
38. Johnston CC, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-7.
39. Lee WTK, Leung SSR, Leung DMY, Cheng JCY. A follow-up study on the effects of calcium-supplement withdrawal and puberty on bone acquisition of children. Am J Clin Nutr 1996;64: 71-7.
40. Espallargues M, Sampietro-Colom L, Estrada MD, Sola M, del Rio L, Setoain J, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporosi Int 2001;12:811-22.
41. Castro J, Zaro L, Pons F, Halperin I, Toro J. Predictors of bone mineral density reduction in adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2000;39:1365-70.
42. Slemenda CW, Miller JZ, Hui SL, Reister TK, Johnston CC. Role of physical activity in the development of skeletal mass in children. J Bone Miner Res 1991;6:1227-33.
43. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC. Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction of heritability estimates. J Bone Miner Res 1991;6:561-7.
44. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Ebert S. Genetic determinants of bone mass in adults: a twin study. J Clin Invest 1987;80:706-10.
45. Jouanny P, Fuillemin F, Kuntz C, Jeandel C, Pourel J. Environmental and genetic factors affecting bone mass. Arthritis Rheum 1994;38:61-7.
46. Morrison NA, Cheng QJ, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-7.
47. Uitterlinden AG, Pols HA, Burger H, Huang Q, Van Daele PL, Van Duijn CM, et al. A large-scale population-based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. J Bone Miner Res 1996;11:1241-8.
48. Majumdar S, Lin J, Link T, Millard J, Augat P, Ouyang X, et al. Fractal analysis of radiographs: assessment of trabecular bone structure and prediction of elastic modulus and strength. Med Phys 1999;26:1330-40.
49. Lau E, Cooper C. The epidemiology of osteoporosis: the oriental perspective in a world context. Clin Orthop 1996;323:65-74.
50. Jiang Y, Zhao J, Augat P, Ouyang X, Lu Y, Majumdar S, et al. Trabecular bone mineral and calculated structure of human bone specimens scanned by peripheral quantitative computed tomography: relation to biomechanical properties. J Bone Miner Res 1998;13:1783-90.
51. Sartoris DJ, Resnick D. Dual-energy radiographic absorptiometry for bone densitometry: current status and perspective. AJR 1989;152:241-6.
52. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137-45.
53. Molgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF. Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997;76:9-15.
54. Loyd T, Rollings N, Andon MB, Demers LM, Eggli DF, Kiesselgourst K, et al. Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab 1992;75: 383-7.
55. Fogelman I, Ryan P. Measurement of bone mass. Bone 1992;13:S23-8.
56. Saggese G, Baroncelli GI, Bertelloni S. Osteoporosis in children and adolescents: diagnosis, risk factors and prevention. J Ped Endocrinol Metab 2001;14:833-59.
57. Fuerst T, Gluer CC, Genant HK. Quantitative ultrasound. Eur J Radiol 1995;20:188-92.
58. Falcini F, Bindi G, Ermini M, Galluzzi F, Poggi G, Rossi S, et al. Comparison of quantitative calcaneal ultrasound and dual energy X-ray absorptiometry in the evaluation of osteoporotic risk in children with chronic rheumatic diseases. Calcif Tissue Int 2000;67:19-23.
59. Zak M, Hassager C, Lovell DJ, Nielsen S, Henderson CJ, Pedersen FK. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis. Arthritis Rheum 1999;42: 790-8.
60. Haugen M, Lien G, Flatø B, Kvammen J, Vinje O, Sørskaar D, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum 2000;43:1504-10.
61. Ragab AH, Frech RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970;25:580-5.
62. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984;11:13-6.
63. Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996;132:184-7.
64. Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993;52:582-5.
65. Stein B, Takizawa M, Katz I, Joffe I, Berlin J, Fallon M, et al. Salmon calcitonin prevents cyclosporin-A-induced high turnover bone loss. Endocrinology 1991;129:92-8.
66. Buchinsky FJ, Ma Y, Mann GN, Rucinski B, Bryer HP, Romero DF, et al. T lymphocytes play a critical role in the development of cyclosporin-A-induced osteopenia. Endocrinology 1996;137: 2278-85.
67. Hillman L, Cassidy JT, Johnson L, Lee D, Allen SH. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr 1994;124:910-6.
68. Reed AM, Haugen M, Pachman LP, Langman CB. Repair of osteopenia in children with juvenile rheumatoid arthritis. J Pediatr 1993;122:693-6.
69. Reeve J, Loftus J, Hesp R, Ansell BM, Wright DJ, Woo PM. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993;20:1189-95.
70. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996;39: 746-57.
71. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, et al. Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1967-75.
72. Reed A, Haugen M, Pachman LM, Langman CB. Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. J Pediatr 1990;116:574-80.
73. Polito C, Strano CG, Rea L, Alessio M, Iammarrone CS, Todisco N, et al. Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis. Ann Rheum Dis 1995;54:193-6.
74. Hopp R, Degan J, Gallagher JC, Cassidy JT Estimation of bone mineral density in children with juvenile rheumatoid arthritis. J Rheumatol 1991;18:1235-9.
75. Henderson CJ, Specker BL, Sierra RI, Campaigne BM, Lovell DJ. Total-body bone mineral content in non -corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:531-40.
76. Rabinovich CE, Amoroso K, Henderson RC, Kredich DW. Bone mineral density in patients with juvenile arthritis. Arthritis Rheum 1995;38:S285.
77. Rabinovich CE, Wagner-Weiner L, Wuellner J, Spencer C. Osteoporosis in juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:S323.
78. Reed A, Haugen M, Pachman LM, Langman CB. 25-Hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: short-term effects on serum osteocalcin levels and bone density. J Pediatr 1991;119:657-60.
79. Warady BD, Lindsley CB, Robinson FG, Lukert BP. Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol 1994;21:530-5.
80. Allgrove J. Bisphosphanates. Arch Dis Child 1997;76:73-5.
81. Papapoulos SE, Landman JO, Vijvoet OLM, Lowik CWGM, Valkema R, Pauwels EKJ, et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13:S41-9.
82. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 2001:202-11.
83. Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992;184:249-54.
84. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, et al. Intravenous pamidonate treatment in osteogenesis imperfecta. J Pediatr 1997;131:622-5.
85. Glorieux FJ, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-95.
86. Brumsen C, Hamdy NA, Papapoulous SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76: 266-83.
87. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue disease in children: a prospective multicenter study. Arthritis Rheum 2000;43:1960-6.